CO5700833A2 - Vacuna - Google Patents

Vacuna

Info

Publication number
CO5700833A2
CO5700833A2 CO05056623A CO05056623A CO5700833A2 CO 5700833 A2 CO5700833 A2 CO 5700833A2 CO 05056623 A CO05056623 A CO 05056623A CO 05056623 A CO05056623 A CO 05056623A CO 5700833 A2 CO5700833 A2 CO 5700833A2
Authority
CO
Colombia
Prior art keywords
protein
hcv
encodes
expression cassette
vaccine
Prior art date
Application number
CO05056623A
Other languages
English (en)
Spanish (es)
Inventor
Sara Brett
Pail Andrew Hamblin
Louise Ogilvie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5700833A2 publication Critical patent/CO5700833A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CO05056623A 2002-11-15 2005-06-10 Vacuna CO5700833A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine

Publications (1)

Publication Number Publication Date
CO5700833A2 true CO5700833A2 (es) 2006-11-30

Family

ID=9947928

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05056623A CO5700833A2 (es) 2002-11-15 2005-06-10 Vacuna

Country Status (21)

Country Link
US (4) US20060135451A1 (https=)
EP (2) EP1560844A1 (https=)
JP (2) JP2006524181A (https=)
KR (2) KR20050085009A (https=)
CN (2) CN1738834A (https=)
AR (1) AR041964A1 (https=)
AU (2) AU2003288072A1 (https=)
BR (2) BR0316291A (https=)
CA (2) CA2504715A1 (https=)
CO (1) CO5700833A2 (https=)
GB (1) GB0226722D0 (https=)
IS (2) IS7830A (https=)
MA (2) MA27700A1 (https=)
MX (2) MXPA05005203A (https=)
NO (2) NO20052136L (https=)
NZ (2) NZ539998A (https=)
PL (2) PL376967A1 (https=)
RU (2) RU2323744C2 (https=)
TW (1) TW200502246A (https=)
WO (2) WO2004046175A1 (https=)
ZA (2) ZA200503802B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN102614510A (zh) 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
EP1981537B1 (en) * 2006-01-04 2015-08-26 GlaxoSmithKline Biologicals S.A. HCV E1E2 MF59-adjuvanted protein plus HCV E1E2 encoding alphavirus vector for eliciting HCV-specific T cells.
ATE556136T1 (de) * 2006-03-09 2012-05-15 Transgene Sa Nichtstrukturelles hcv-fusionsprotein
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
JP2011529077A (ja) * 2008-07-24 2011-12-01 アデュロ バイオテック Ｃ型肝炎の治療のための組成物および方法
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
CN119504957B (zh) * 2025-01-16 2025-04-25 中山大学 一种佐剂及其在制备疫苗中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
DE69533167D1 (de) * 1994-10-05 2004-07-22 Apollon Inc Impfstoffe gegen den hepatitis b und c virus
AU5924396A (en) * 1995-05-22 1996-12-11 Bionova Corporation Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)
AU717542B2 (en) * 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
WO2001004149A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
CA2389206C (en) * 1999-10-27 2011-01-04 Chiron Corporation Activation of hcv-specific t cells
CA2390082C (en) * 1999-11-24 2010-06-29 Chiron Corporation Novel hcv non-structural polypeptide
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2005113691A (ru) 2006-01-27
BR0316244A (pt) 2005-10-04
RU2363492C2 (ru) 2009-08-10
ZA200503802B (en) 2006-08-30
NO20052149D0 (no) 2005-05-02
MXPA05005202A (es) 2006-01-27
IS7831A (is) 2005-04-28
US20060135451A1 (en) 2006-06-22
JP2006524181A (ja) 2006-10-26
BR0316291A (pt) 2005-10-11
KR20050085009A (ko) 2005-08-29
JP2006518331A (ja) 2006-08-10
AU2003288072A1 (en) 2004-06-15
PL376967A1 (pl) 2006-01-23
NZ539999A (en) 2008-03-28
IS7830A (is) 2005-04-28
RU2005113692A (ru) 2006-01-27
CA2504715A1 (en) 2004-06-03
CN1738834A (zh) 2006-02-22
AU2003288084A1 (en) 2004-06-15
CN1738833A (zh) 2006-02-22
AR041964A1 (es) 2005-06-01
NO20052149L (no) 2005-07-11
RU2323744C2 (ru) 2008-05-10
ZA200503803B (en) 2006-08-30
US20090232847A1 (en) 2009-09-17
NO20052136D0 (no) 2005-05-02
US20090104231A1 (en) 2009-04-23
NZ539998A (en) 2008-04-30
TW200502246A (en) 2005-01-16
KR20050085010A (ko) 2005-08-29
US20060246090A1 (en) 2006-11-02
GB0226722D0 (en) 2002-12-24
MA27700A1 (fr) 2006-01-02
MXPA05005203A (es) 2006-01-27
WO2004046176A1 (en) 2004-06-03
EP1560845A1 (en) 2005-08-10
WO2004046175A1 (en) 2004-06-03
MA27699A1 (fr) 2006-01-02
NO20052136L (no) 2005-07-11
CA2504654A1 (en) 2004-06-03
PL376882A1 (pl) 2006-01-09
EP1560844A1 (en) 2005-08-10

Similar Documents

Publication Publication Date Title
CO5700833A2 (es) Vacuna
ES2191006T3 (es) Redireccion de la inmunidad celular por quimeras de receptor.
ES2159197T3 (es) Procedimiento y aparato para convertir una cadena de bits mpeg-2 en una cadena de bits compatible con smpte-259.
WO2002002764A3 (en) High molecular weight derivatives of vitamin k-dependent polypeptides
WO2004023703A3 (en) Encoding and decoding of digital data using cues derivable at a decoder
DE50109347D1 (de) Weichkapseln enthaltend Polymerisate von Vinylestern und Polyethern, deren Verwendung und Herstellung
SE0303497D0 (sv) Image processing
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
DE69926647D1 (de) Durch molekulares pathogenicid vermittelte krankheitsresistenz in pflanzen
DK1546316T3 (da) Mutant E. Coli-AppA-fytaseenzymer og naturlige varianter deraf, nukleinsyrer, der koder for sådanne fytaseenzymer, vektorer og værtsceller, som inkorporerer disse og fremgangsmåder til at fremstille og anvende disse
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
SI1675956T1 (sl) Minimalno zaporedje dna, ki deluje kot izolirni element kromatina in njegova uporaba pri ekspresiji proteinov
IL151746A0 (en) Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
EP1549073A3 (en) Dynamic packet size control for mpeg-4 data partition mode
DE60114804D1 (de) Konstruierte fluoreszenzproteine mit langen wellenlängen
DE60139544D1 (de) Veränderte, fluoreszierende proteine
ES2153358T3 (es) Procedimientos para la seleccion de celulas huespedes recombinantes que expresan altos niveles de una proteina deseada.
EP1449860A4 (en) NEW FLUOROPOLYMER, THESE RESISTANT COMPOSITIONS, AND NEW FLUORMONOMERS
AR033745A1 (es) Sistema kerdock de codificacion y decodificacion para datos de mapas.
DE60118359D1 (de) Humanische pellino-polypeptide
GB0101124D0 (en) DNA element and assoc
EP1727053A3 (en) Method and system for spatial, appearance and acoustic coding of words and sentences
DE60233875D1 (de) Attenuierter circovirus
SG185137A1 (en) Biologically active peptides
DE60137607D1 (de) Substituierte cyclohexene

Legal Events

Date Code Title Description
FC Application refused